Cambridge Healthtech Institute’s 3rd Annual
Next-Generation Immunotherapies
New Therapeutic Modalities and Emerging Indications
13 November 2025
Cambridge Healthtech Institute's Next-Generation Immunotherapies conference highlights new modalities that are continuing to revolutionize the treatment landscape, with advancements in immune cell modulators, immunocytokines, immunoconjugates, and personalised cancer vaccines. This conference showcases the latest breakthroughs in immuno-oncology and immune-mediated inflammatory diseases. Industry pioneers and academic visionaries will share insights on accelerating clinical translation and navigating resistance mechanisms for advanced therapeutics.
Coverage will include, but is not limited to:
Immune Cell Modulators
- T cell engagers
- NK cell engagers
- Macrophage/Myeloid cell engagers
- B cell depleting bispecifics in autoimmunity
Autologous and Allogeneic Cell Therapies in Auto-immune, Oncology and other Indications
Combination Therapies with Immune Checkpoint Inhibitors
- PD-1/VEGF
- Molecules targeting TIGIT, TIM-3, LAG3, VISTA, BTLA, SIRPα
- Overcoming resistance/tolerance to treatment
- Addition of targeted T cell enhancers to T cell engagers (CD2, 4-1BB etc)
Immuno-Cytokines and Immuno-Conjugates
- Balancing safety and efficacy
- Pharmacodynamic and pharmacokinetic considerations
Cancer Vaccines and Neoantigens
- Immune checkpoint combinations with mRNA-based immunotherapies
- Optimisation of neoantigen targets for personalised vaccines
- mRNA vaccines in pancreatic cancer
The deadline for priority consideration is 28 March 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: